Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20‐year single‐center experience & propensity‐score matching

Abstract Background and Objectives Despite the standard interval of 6−8 weeks between neoadjuvant chemoradiotherapy (nCRT) and surgery, it is debated whether an interval of >8 weeks increases the pathologic complete response (pCR) rate. We investigated the interval between nCRT and surgery, and its impact on oncological outcomes and postoperative complications in patients with locally advanced rectal cancer. Methods We retrospectively reviewed patients with rectal cancer who underwent total mesorectal excision after long‐course nCRT between 2000 and 2020. They were divided into two groups—those who underwent surgery at 6−8 and >8 weeks after nCRT. Surgical outcomes (stoma rate and postoperative complications), pCR, tumor regression grade (TRG), recurrence‐free survival (RFS), and overall survival (OS) were compared. Results We selected 770/1153 patients with rectal cancer, including 502 and 268 patients surgically treated at 6−8 and >8 weeks after nCRT, respectively. The pCR rates were similar between the two groups (14.7% vs. 15.3%, p = 0.836), while the TRG was significantly better in the >8 weeks group ( p = 0.267). Additionally, the postoperative complications, recurrence, 5‐year RFS, and OS rates were not significantly different between the two groups. Conclusions Although tumor regression increased in the >8 weeks group, the oncological benefits of surgery >8 weeks after nCRT remain uncertain.